Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Elizabeth Gordon is active.

Publication


Featured researches published by Elizabeth Gordon.


NeuroImage | 2011

The structural neuroanatomy of music emotion recognition: Evidence from frontotemporal lobar degeneration

Rohani Omar; Susie M.D. Henley; Jonathan W. Bartlett; Julia C. Hailstone; Elizabeth Gordon; Disa Sauter; Chris Frost; Sophie K. Scott; Jason D. Warren

Despite growing clinical and neurobiological interest in the brain mechanisms that process emotion in music, these mechanisms remain incompletely understood. Patients with frontotemporal lobar degeneration (FTLD) frequently exhibit clinical syndromes that illustrate the effects of breakdown in emotional and social functioning. Here we investigated the neuroanatomical substrate for recognition of musical emotion in a cohort of 26 patients with FTLD (16 with behavioural variant frontotemporal dementia, bvFTD, 10 with semantic dementia, SemD) using voxel-based morphometry. On neuropsychological evaluation, patients with FTLD showed deficient recognition of canonical emotions (happiness, sadness, anger and fear) from music as well as faces and voices compared with healthy control subjects. Impaired recognition of emotions from music was specifically associated with grey matter loss in a distributed cerebral network including insula, orbitofrontal cortex, anterior cingulate and medial prefrontal cortex, anterior temporal and more posterior temporal and parietal cortices, amygdala and the subcortical mesolimbic system. This network constitutes an essential brain substrate for recognition of musical emotion that overlaps with brain regions previously implicated in coding emotional value, behavioural context, conceptual knowledge and theory of mind. Musical emotion recognition may probe the interface of these processes, delineating a profile of brain damage that is essential for the abstraction of complex social emotions.


Neurology | 2016

Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia

Jonathan D. Rohrer; Ione O.C. Woollacott; Katrina M. Dick; Elizabeth Gordon; Alexander Fellows; Jamie Toombs; Ronald Druyeh; M. Jorge Cardoso; Sebastien Ourselin; Jennifer M. Nicholas; Niklas Norgren; Simon Mead; Ulf Andreasson; Kaj Blennow; Jonathan M. Schott; Nick C. Fox; Jason D. Warren; Henrik Zetterberg

Objective: To investigate serum neurofilament light chain (NfL) concentrations in frontotemporal dementia (FTD) and to see whether they are associated with the severity of disease. Methods: Serum samples were collected from 74 participants (34 with behavioral variant FTD [bvFTD], 3 with FTD and motor neuron disease and 37 with primary progressive aphasia [PPA]) and 28 healthy controls. Twenty-four of the FTD participants carried a pathogenic mutation in C9orf72 (9), microtubule-associated protein tau (MAPT; 11), or progranulin (GRN; 4). Serum NfL concentrations were determined with the NF-Light kit transferred onto the single-molecule array platform and compared between FTD and healthy controls and between the FTD clinical and genetic subtypes. We also assessed the relationship between NfL concentrations and measures of cognition and brain volume. Results: Serum NfL concentrations were higher in patients with FTD overall (mean 77.9 pg/mL [SD 51.3 pg/mL]) than controls (19.6 pg/mL [SD 8.2 pg/mL]; p < 0.001). Concentrations were also significantly higher in bvFTD (57.8 pg/mL [SD 33.1 pg/mL]) and both the semantic and nonfluent variants of PPA (95.9 and 82.5 pg/mL [SD 33.0 and 33.8 pg/mL], respectively) compared with controls and in semantic variant PPA compared with logopenic variant PPA. Concentrations were significantly higher than controls in both the C9orf72 and MAPT subgroups (79.2 and 40.5 pg/mL [SD 48.2 and 20.9 pg/mL], respectively) with a trend to a higher level in the GRN subgroup (138.5 pg/mL [SD 103.3 pg/mL). However, there was variability within all groups. Serum concentrations correlated particularly with frontal lobe atrophy rate (r = 0.53, p = 0.003). Conclusions: Increased serum NfL concentrations are seen in FTD but show wide variability within each clinical and genetic group. Higher concentrations may reflect the intensity of the disease in FTD and are associated with more rapid atrophy of the frontal lobes.


Neurology | 2010

Measuring disease progression in frontotemporal lobar degeneration: A clinical and MRI study

Elizabeth Gordon; Jonathan D. Rohrer; Lois G. Kim; Rohani Omar; Nick C. Fox; Jason D. Warren

Objectives: There is currently much interest in biomarkers of disease activity in frontotemporal lobar degeneration (FTLD). We assessed MRI and behavioral measures of progression in a longitudinal FTLD cohort. Methods: Thirty-two patients with FTLD (11 behavioral variant frontotemporal dementia [bvFTD], 11 semantic dementia [SemD], 10 progressive nonfluent aphasia [PNFA]) and 24 age-matched healthy controls were assessed using volumetric brain MRI and standard behavioral measures (Mini-Mental State Examination, Frontal Assessment Battery, Clinical Dementia Rating Scale, Neuropsychiatric Inventory with Caregiver Distress scale) at baseline and 1 year later. A semi-automated image registration protocol was used to calculate annualized rates of brain atrophy (brain boundary shift integral [BBSI]) and ventricular expansion (ventricular boundary shift integral [VBSI]). Associations between these rates and changes in behavioral indices were investigated. Results: Rates of whole brain atrophy were greater in the entire FTLD cohort and in each subgroup compared with controls (all p ≤ 0.004). Rates of ventricular expansion were greater in the entire cohort (p < 0.001) and the SemD (p = 0.002) and PNFA (p = 0.05) subgroups compared with controls. Changes in Mini-Mental State Examination, Frontal Assessment Battery, and Clinical Dementia Rating Scale scores were associated with MRI measures of progression, though not uniformly across FTLD subgroups. Both BBSI and VBSI yielded feasible sample size estimates for detecting meaningful treatment effects in SemD and PNFA language subgroups. Sample sizes were substantially larger using MRI biomarkers for the bvFTD subgroup, and using behavioral biomarkers in general. Conclusions: Semi-automated MRI atrophy measures are potentially useful objective biomarkers of progression in frontotemporal lobar degeneration (FTLD); however, careful stratification of FTLD subtypes will be important in future clinical trials of disease-modifying therapies.


Neuropathology and Applied Neurobiology | 2014

A pathogenic progranulin mutation and C9orf72 repeat expansion in a family with frontotemporal dementia

Tammaryn Lashley; Jonathan D. Rohrer; Colin J. Mahoney; Elizabeth Gordon; Jon Beck; Simon Mead; Jason D. Warren; Tamas Revesz

Frontotemporal lobar degeneration (FTLD) is a progressive neurodegenerative disease and is the second most common form of young onset dementia after Alzheimers disease (AD). An autosomal dominant pattern of inheritance is present in around 25–50% of FTLD cases indicating a strong genetic component. Major pathogenic mutations of FTLD have been demonstrated independently in the progranulin (GRN) gene and the C9orf72 hexanucleotide expansion repeat. In this study we present a family that have been identified as carrying both a GRN Cys31fs mutation and the C9orf72 hexanucleotide expansion repeat.


Journal of Alzheimer's Disease | 2015

Altered Sense of Humor in Dementia

Camilla N. Clark; Jennifer M. Nicholas; Elizabeth Gordon; Hannah L. Golden; Miriam H. Cohen; Felix Woodward; Kirsty Macpherson; Catherine F. Slattery; Catherine J. Mummery; Jonathan M. Schott; Jonathan D. Rohrer; Jason D. Warren

Sense of humor is potentially relevant to social functioning in dementias, but has been little studied in these diseases. We designed a semi-structured informant questionnaire to assess humor behavior and preferences in patients with behavioral variant frontotemporal dementia (bvFTD; n = 15), semantic dementia (SD; n = 7), progressive nonfluent aphasia (PNFA; n = 10), and Alzheimer’s disease (AD; n = 16) versus healthy age-matched individuals (n = 21). Altered (including frankly inappropriate) humor responses were significantly more frequent in bvFTD and SD (all patients) than PNFA or AD (around 40% of patients). All patient groups liked satirical and absurdist comedy significantly less than did healthy controls. This pattern was reported premorbidly for satirical comedy in bvFTD, PNFA, and AD. Liking for slapstick comedy did not differ between groups. Altered sense of humor is particularly salient in bvFTD and SD, but also frequent in AD and PNFA. Humor may be a sensitive probe of social cognitive impairment in dementia, with diagnostic, biomarker and social implications.


Journal of Neurochemistry | 2016

Advances in neuroimaging in frontotemporal dementia.

Elizabeth Gordon; Jonathan D. Rohrer; Nick C. Fox

Frontotemporal dementia (FTD) is a clinically and neuroanatomically heterogeneous neurodegenerative disorder with multiple underlying genetic and pathological causes. Whilst initial neuroimaging studies highlighted the presence of frontal and temporal lobe atrophy or hypometabolism as the unifying feature in patients with FTD, more detailed studies have revealed diverse patterns across individuals, with variable frontal or temporal predominance, differing degrees of asymmetry, and the involvement of other cortical areas including the insula and cingulate, as well as subcortical structures such as the basal ganglia and thalamus. Recent advances in novel imaging modalities including diffusion tensor imaging, resting‐state functional magnetic resonance imaging and molecular positron emission tomography imaging allow the possibility of investigating alterations in structural and functional connectivity and the visualisation of pathological protein deposition. This review will cover the major imaging modalities currently used in research and clinical practice, focusing on the key insights they have provided into FTD, including the onset and evolution of pathological changes and also importantly their utility as biomarkers for disease detection and staging, differential diagnosis and measurement of disease progression. Validating neuroimaging biomarkers that are able to accomplish these tasks will be crucial for the ultimate goal of powering upcoming clinical trials by correctly stratifying patient enrolment and providing sensitive markers for evaluating the effects and efficacy of disease‐modifying therapies.


Neurology | 2017

Lower cardiac index levels relate to lower cerebral blood flow in older adults

Angela L. Jefferson; Dandan Liu; Deepak K. Gupta; Kimberly R. Pechman; Jennifer M. Watchmaker; Elizabeth Gordon; Swati Rane; Susan P. Bell; Lisa A. Mendes; L. Taylor Davis; Katherine A. Gifford; Timothy J. Hohman; Thomas J. Wang; Manus J. Donahue

Objective: To assess cross-sectionally whether lower cardiac index relates to lower resting cerebral blood flow (CBF) and cerebrovascular reactivity (CVR) among older adults. Methods: Vanderbilt Memory & Aging Project participants free of stroke, dementia, and heart failure were studied (n = 314, age 73 ± 7 years, 59% male, 39% with mild cognitive impairment). Cardiac index (liters per minute per meter squared) was quantified from echocardiography. Resting CBF (milliliters per 100 grams per minute) and hypercapnia-induced CVR were quantified from pseudo-continuous arterial spin-labeling MRI. Linear regressions with ordinary least-square estimates related cardiac index to regional CBF, with adjustment for age, education, race/ethnicity, Framingham Stroke Risk Profile score (systolic blood pressure, antihypertensive medication use, diabetes mellitus, current cigarette smoking, left ventricular hypertrophy, prevalent cardiovascular disease [CVD], atrial fibrillation), APOE ε4 status, cognitive diagnosis, and regional tissue volume. Results: Lower cardiac index corresponded to lower resting CBF in the left (β = 2.4, p = 0.001) and right (β = 2.5, p = 0.001) temporal lobes. Results were similar when participants with prevalent CVD and atrial fibrillation were excluded (left temporal lobe β = 2.3, p = 0.003; right temporal lobe β = 2.5, p = 0.003). Cardiac index was unrelated to CBF in other regions assessed (p > 0.25) and CVR in all regions (p > 0.05). In secondary cardiac index × cognitive diagnosis interaction models, cardiac index and CBF associations were present only in cognitively normal participants and affected a majority of regions assessed with effects strongest in the left (p < 0.0001) and right (p < 0.0001) temporal lobes. Conclusions: Among older adults without stroke, dementia, or heart failure, systemic blood flow correlates with cerebral CBF in the temporal lobe, independently of prevalent CVD, but not CVR.


Neurocase | 2014

A cognitive chameleon: Lessons from a novel MAPT mutation case

Yuying Liang; Elizabeth Gordon; Jonathan D. Rohrer; Laura E. Downey; Rohan de Silva; Hans Rolf Jäger; Jennifer M. Nicholas; Marc Modat; M. Jorge Cardoso; Colin J. Mahoney; Jason D. Warren; Nick C. Fox; Diana Caine

We report a case of frontotemporal dementia caused by a novel MAPT mutation (Q351R) with a remarkably long amnestic presentation mimicking familial Alzheimer’s disease. Longitudinal clinical, neuropsychological and imaging data provide convergent evidence for predominantly bilateral anterior medial temporal lobe involvement consistent with previously established neuroanatomical signatures of MAPT mutations. This case supports the notion that the neural network affected in MAPT mutations is determined to a large extent by the underlying molecular pathology. We discuss the diagnostic significance of anomia in the context of atypical amnesia and the impact of impaired episodic and semantic memory systems on autobiographical memory.


Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring | 2017

The clinical, neuroanatomical, and neuropathologic phenotype of TBK1-associated frontotemporal dementia: A longitudinal case report

Carolin Koriath; Martina Bocchetta; Ione O.C. Woollacott; Penny Norsworthy; Javier Simón-Sánchez; Cornelis Blauwendraat; Katrina M. Dick; Elizabeth Gordon; S Harding; Nick C. Fox; Sebastian J. Crutch; Jason D. Warren; Tamas Revesz; Tammaryn Lashley; Simon Mead; Jonathan D. Rohrer

Mutations in the TANK‐binding kinase 1 (TBK1) gene have recently been shown to cause frontotemporal dementia (FTD). However, the phenotype of TBK1‐associated FTD is currently unclear.


Journal of Neurology, Neurosurgery, and Psychiatry | 2016

The habenula: an under-recognised area of importance in frontotemporal dementia?

Martina Bocchetta; Elizabeth Gordon; Charles R. Marshall; Catherine F. Slattery; M. Jorge Cardoso; David M. Cash; Miklos Espak; Marc Modat; Sebastien Ourselin; Giovanni B. Frisoni; Jonathan M. Schott; Jason D. Warren; Jonathan D. Rohrer

Behavioural variant frontotemporal dementia (bvFTD) is a neurodegenerative disorder characterised by atrophy of the frontal and temporal lobes and progressive behavioural and cognitive impairment. Some behavioural symptoms such as craving for food, alcohol or drugs, and hypersexuality are suggestive of abnormal reward processing. The reward circuit is formed by a number of different structures including the orbitofrontal cortex, ventral striatum (in particular the nucleus accumbens), ventral pallidum, anterior cingulate cortex, thalamus, hypothalamus, midbrain and habenula.1 This complex network combines information about motivation, cognitive planning and motor control to develop an appropriate goal-directed response to external environmental stimuli. Many of the brain structures belonging to the reward circuit have been found to be atrophic in bvFTD,2 supporting the theory that impairment of the reward system is an important factor in this disease. Among these structures, the habenula, found medial to the posterior thalamus, is uniquely positioned to participate in reward processing, acting as a convergence point for the limbic system and basal ganglia circuits,3 ,4 and therefore playing a pivotal role in the integration of information required to generate goal-directed behaviours. Despite this key role, it has yet to be investigated in bvFTD. The aim of this study was to investigate the volume of the habenula in a cohort of patients with bvFTD, hypothesising that it would be smaller than in healthy controls as well as an age-matched group of patients with Alzheimer’s disease (AD) who typically do not show impairment of reward behaviour. We also hypothesised that the habenula would show comparable atrophy to other key areas in the reward network in bvFTD. Fifteen participants fulfilling criteria for the diagnosis of bvFTD (including eight with a MAPT mutation and four with a pathogenic expansion in the C9orf72 gene) were recruited consecutively from a tertiary referral cognitive …

Collaboration


Dive into the Elizabeth Gordon's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jason D. Warren

UCL Institute of Neurology

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Nick C. Fox

UCL Institute of Neurology

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Katrina M. Dick

UCL Institute of Neurology

View shared research outputs
Top Co-Authors

Avatar

Simon Mead

UCL Institute of Neurology

View shared research outputs
Top Co-Authors

Avatar

David M. Cash

University College London

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge